Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Earnings, H1 FY2026
Net loss improved to DKK -2.7m, with strengthened IP and ongoing licensing discussions.
2025
Earnings, H2 FY2025
Annual
Loss before tax narrowed to DKK -26.4 million amid clinical progress and ongoing funding efforts.
Investor Update
Strong clinical progress in repurposed therapies for cancer prevention and peritonitis.
Earnings, H1 FY2025
Net loss improved, no revenue yet, and Portinho S.A. receivable remains a key focus.
Investor Update
2025 guidance targets 11 mDKK revenue as pipeline assets advance toward licensing and clinical trials.
2024
Earnings, Q4 FY2024
Annual
2024 loss in line with expectations; capital strengthened, first revenue expected late 2025.
Earnings, Q3 FY2024
Capital actions and a new Japanese patent drive strategic progress amid ongoing losses.
Investor Update
Capital raise strengthens balance sheet, reduces debt, and targets licensing deal by 2025.
Earnings, Q2 FY2024
H1 2024 loss aligns with expectations; clinical progress and Portinho receivable recovery ongoing.
Investor Update
First partnership targeted for 2025, focusing on strategic fit and global clinical networks.
Earnings, Q1 FY2024
Q1 loss reached DKK 7.2m as clinical progress advanced and Portinho recovery remained unresolved.
Investor Update
Six repositioned candidates target licensing, while CSR centres on patients and bowel-disease awareness.
2023
Earnings, Q4 FY2023
Annual
Pipeline progress continued, but zero revenue and Portinho-related funding risk define the outlook.